header logo image


Page 19«..10..18192021..»

Archive for the ‘Neuropathy’ Category

NeuroMetrix Reports Q4 and Full Year 2019 Financial Results – BioSpace

Tuesday, January 28th, 2020

WOBURN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc., (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019.

The Company develops and commercializes diagnostic and therapeutic neurostimulation-based medical devices. The Company has three commercial products. DPNCheck is a point-of-care diagnostic test for peripheral neuropathies including diabetic peripheral neuropathy (DPN). ADVANCE is a point-of-care diagnostic test primarily used for carpal tunnel syndrome. Quell is a wearable neurostimulation device that is available over-the-counter for symptomatic relief of chronic pain.

Q4 2019 Highlights:

"Although we were disappointed by the overall drop in revenue from the year-ago period, we expected this outcome given our large reduction in operating expenses, attention to improved gross margins and overall focus on long term growth and profitability. We believe we made important progress against these objectives. We experienced strong demand for DPNCheck during the fourth quarter which is typically our slowest period. This momentum should carry into 2020 as new Medicare Advantage accounts come on board and we expect a rebound in international sales. Our enthusiasm for the DPNCheck business is reflected in our investment in the next generation device to be launched in late 2020, said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. Our Quell business is focused on cost-efficient advertising combined with an exclusively direct-to-consumer model via our QuellRelief.com website and exploration of new markets. We believe this technology is unique and represents an attractive long term opportunity for the Company. Finally, we are actively engaged with the Federal Trade Commission(FTC) to resolve the previously disclosed matter which is centered on earlier Quell advertising.

Financials:Regarding the fourth quarter 2019, total revenues were $1.7 million, down 54% from $3.7 million in the prior year period. Gross margin was $1.1 million versus $1.7 million in Q4 2018. The gross margin rate of 62.2% improved from 46.9% in Q4 2018. Operating expenses were $2.7 million, a reduction of $1.9 million from $4.6 million in Q4 2018. Collaboration income of $0.6 million was recognized in Q4 2019. Net loss was $1.1 million compared to $2.8 million in Q4 2018. Net cash usage from operations was $.7 million, a reduction from $2.7 million in Q4 2018. The Company ended the quarter with cash of $3.1 million.

Regarding the full year 2019, total revenues were $9.3 million, down from $16.1 million in 2018. Gross margin was $2.2 million after inventory-related write-downs of $2.6 million. 2018 gross margin was $7.4 million. Operating expenses were $13.8 million versus $19.7 million in 2018. Income from the GSK collaboration was $7.7 million in comparison with $12.3 million in 2018. Net loss was $3.8 million versus net income of $24 thousand in 2018.

Company to Host Live Conference Call and WebcastNeuroMetrix will host a conference call at 8:00 a.m. Eastern today, January 27, 2020. The call may be accessed in the United States at 844-787-0799, international at 661-378-9630 using confirmation code 6728609. A replay will be available starting two hours after the call at 855-859-2056 United States and 404-537-3406 international using confirmation code 6728609. It will remain available for one week. The call will also be webcast and accessible at http://www.NeuroMetrix.com under "Investor Relations".

About NeuroMetrixNeuroMetrix is a leading developer of diagnostic and therapeutic neurostimulation-based medical devices. DPNCheck is a point-of-care diagnostic test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. ADVANCE is a point-of-care nerve conduction study that evaluates multiple nerves including the median nerve, which is affected in carpal tunnel syndrome. Quell is a wearable neurostimulation device for symptomatic relief of chronic pain that is available over-the-counter. For more information, please visit NeuroMetrix.com.

Safe Harbor StatementThe statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the companys or managements expectations regarding the business, as well as events that could have a meaningful impact on the companys revenues and cash resources. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, estimates of future performance, the ability to successfully develop, receive regulatory clearance, commercialize and achieve market acceptance for any products, and the final outcome of the ongoing Federal Trade Commission civil investigative demand enforcement action involving Quell. There can be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the companys most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with the Securities and Exchange Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.

Source: NeuroMetrix, Inc.

Thomas T. HigginsSVP and Chief Financial Officer781-314-2761neurometrix.ir@neurometrix.com

NeuroMetrix, Inc.Statements of Operations(Unaudited)

Condensed Balance Sheets(Unaudited)

See the article here:
NeuroMetrix Reports Q4 and Full Year 2019 Financial Results - BioSpace

Read More...

The health benefits of lemon water | News – WPSD Local 6

Tuesday, January 28th, 2020

(KPRC)Many people drink lemon water because they think it tastes good, or they think it has some health benefits.

Heres a look at what makes it so great.

The majority of women are walking around dehydrated. Adding lemon to your water might be the motivation you need to drink more.

In doing so, you can reduce sugar cravings and get good antioxidants. And that citrus fruit is packing the potential to decrease your risk of kidney stones or reduce diabetic neuropathy.

Dietitian Erin Gussler with the Whole Health Center in Houston, Texas, says she knows this because of studies done in mice.

And in humans, she says it can relieve morning sickness.

"There was a study that showed that drinking lemon water during pregnancy actually can decrease nausea and vomiting so the study showed that consuming lemon water for 4 days actually decrease nausea and vomiting by 33%, Gussler says.

But there's a catch. To get these benefits you might need lots and we mean lots of lemon. Think one-half to two whole lemons a day!

"Some of the studies were like an obscene amount of lemon. Like, like cups of lemon, Gussler says.

While the amount matters more than anything, the temperature only slightly matters. Warm lemon water can help with constipation more than cold water but be careful not to get essential oils too hot.

"There are some studies that show heating those oils to high can break down so thinking about getting a mix of hot and cold and playing with that just to get maximum benefit of both, Gussler says.

Dentists warn patients not to drink too much lemon since the acidity can damage enamel.

They say to lessen that potential damage, you can try drinking through a straw.

Read the original here:
The health benefits of lemon water | News - WPSD Local 6

Read More...

Diabetic Neuropathy Market Innovations, And Top Companies Forecast To 2029| Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc – Neptune Pine

Friday, January 3rd, 2020

New York City, NY: Jan 2020 Published via (Wired Release) MarketResearch.Biz adds Diabetic Neuropathy Market report to its research report database. It is a thorough study of vital elements of the markets such as drivers, growth opportunities, challenges, restraints, current and upcoming trends, SWOT analysis, and many more among other market influencers and strategic information. After comprehensively analyzing these market parameters, the information is presented in a very organized manner that clearly mentions the growth prospects of the Diabetic Neuropathy market during the forecast period.

Making you aware of the latest innovations, market developments, challenges, and opportunities those are estimated to propel Diabetic Neuropathy market growth, this research report puts you in a top position and gives a chance to make use of every opportunity and upcoming trend which can be changed into significant revenues. Diabetic Neuropathy market analysis is extensive into given categories and segmentation and the report is presented in a chapter-wise section for easy finding of required details.

For competitor study, it covers all key players and their respective business information for the pervasive understanding of the competitive scenario. It also makes insertion of their business strategies and reveals the recent developments among major players along with the data of any known collaborations between them. In brief, the well-presented competitive landscape makes you understand the degree of competition.

Being a worldwide report, distinct regions have been studied with detail regional analysis of North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The regional study helps gain insights on the growth of the market in terms of market size, share, and revenue(USD), thereby revealing the market value, volume, and penetration.

For Better Understanding, Request A Free Pdf SampleCopy Of Diabetic Neuropathy Market Here@ https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.

Competitive Landscape

Global Diabetic Neuropathy market is highly cleft and the key players have used numerous plans such as new product launches, acquisitions, mergers, collaborations, innovation in products, expansions, agreements, joint ventures, and others to increase their footmarks in this market.

Key players profiled in the report include: Actavis Pharma Inc, NeuroMetrix Inc, Astellas Pharma Inc, Meda Pharma GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc, Cephalon Inc, Johnson & Johnson Inc and Boehringer Ingelheim GmbH

Market Segmentation:

Segmentation on the basis of disorder type: Peripheral neuropathy, Autonomic neuropathy, Proximal neuropathy, Focal neuropathy, Segmentation on the basis of treatment: Radiotherapy, Physiotherapy

DONT MISS OUT THIS BIG OFFER (NEW YEAR DISCOUNT) AND SAVE UPTO 25% ON YOUR Diabetic Neuropathy MARKET RESEARCH REPORT BUYING. HURRY UP! LIMITED PERIOD OFFER

ENQUIRE HERE AND FILL OUT THE INFORMATION: https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

There Are 13 Chapters To Extensively Display The Diabetic Neuropathy Market:

Chapter 1: Global Diabetic Neuropathy Market Outlook, Product Introduction, Market Segmentation, Market Study of Regions, Market Dynamics, Constraints, Opportunities and Industry News and Policies.

Chapter 2: Global Diabetic Neuropathy Market Chain Study, Upstream Raw Material Suppliers, Key Players, Production Process Study, Cost Analysis, Market Channels, and Key Downstream Buyers.

Chapter 3: Value Study, Production, Price Analysis and Growth Rate Of Diabetic Neuropathy Market by Type.

Chapter 4: Downstream Features, Consumption and Diabetic Neuropathy Market Share by Application.

Chapter 5: Production Volume, Gross Margin, Price, and Revenue (USD) of Diabetic Neuropathy by Regions.

Chapter 6: Diabetic Neuropathy Production, Consumption, Import/Export by Regions.

Chapter 7: Diabetic Neuropathy Market Regional Status and SWOT Analysis.

Chapter 8: Global Competitive Landscape, Product Description, Company Profiles, Diabetic Neuropathy Market Distribution Status by Major Players.

Chapter 9: Diabetic Neuropathy Market Study and Projection by Type and Application (2020-2029).

Chapter 10: Worldwide Market Analysis and Forecast by Regions (2020-2029).

Chapter 11: Global Industry Features, Key Growth Factors, New Entrants SWOT Study, Study of Investment Feasibility.

Chapter 12: Market Conclusion of the Complete Report.

Chapter 13: Appendix Such as Research Methodology and Information Resources.

Browse More Insight Of This Diabetic Neuropathy Market Research Report Enabled with Respective Tables and Figures at: https://marketresearch.biz/report/diabetic-neuropathy-market/

We also provide customization on reports based on specific client requirement:

1- Country-level and regional analysis according to your choice.

2- Competitive analysis of any market players.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID: inquiry@marketresearch.biz

Website: https://marketresearch.biz/

Link:

Diabetic Neuropathy Market Innovations, And Top Companies Forecast To 2029| Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc - Neptune Pine

Read More...

Leber’s Hereditary Optic Neuropathy, 2019 – Pipeline Review, H2 – ResearchAndMarkets.com – Business Wire

Friday, January 3rd, 2020

DUBLIN--(BUSINESS WIRE)--The "Leber's Hereditary Optic Neuropathy (Leber optic atrophy) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively.

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

Introduction

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Development

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Therapeutics Assessment

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Companies Involved in Therapeutics Development

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drug Profiles

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects

Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) - Product Development Milestones

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hp1wmj

Originally posted here:

Leber's Hereditary Optic Neuropathy, 2019 - Pipeline Review, H2 - ResearchAndMarkets.com - Business Wire

Read More...

Diabetic Neuropathy Market Poised to Take Off by 2026 – Market Research Sheets

Monday, December 30th, 2019

Diabetic Neuropathy Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Diabetic Neuropathy industry overview and then goes into each and every detail.

Diabetic Neuropathy Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Diabetic Neuropathy also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

Diabetic Neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S. Rise in aging population coupled with rise in prevalence of diabetes, the patient pool for diabetic neuropathy will increase significantly, in turn fueling growth of the diabetic neuropathy market.

Diabetic Neuropathy Market competition by top manufacturers/players, with Diabetic Neuropathy sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2018-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/213

In this study, the years considered to estimate the market size of 2018-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

This post was originally published on Market Research Sheets

Read more:

Diabetic Neuropathy Market Poised to Take Off by 2026 - Market Research Sheets

Read More...

3 Affordable Herbs & Vitamins that you should try for nerve pain relief – Explosion

Monday, December 30th, 2019

Nerve pain is a crucial problem that occurs in people who have diabetes or are experiencing the after-effects of chemotherapy. It can be stressful and discomforting if not treated and taken care of by a professional physician. Neuropathy treatment is rather conventional, whereby the physician has to come up with a better way to relieve pain through supplements, vitamins, and herbs. This medication helps in avoiding any treatment that may result in negative side effects on ones nervous system. Consultation is the key approach method once you realize that you have neuropathy. This way, the doctor can guide you on ways that you can avoid nerve pain. Neuropathy mostly affects the hands and feet, making movement challenging to most patients. It also induces muscle weakness and lack of sensation. Nevertheless, there are easy treatments that you can rely on to ensure that your lifestyle does not change. Here are three affordable herbs and vitamins that you should try for nerve pain relief:

1) B Vitamins

Neuropathy is a critical condition that requires you to be keen on the mode of treatment you are taking. Lack of vitamins in the body has been linked with nerve pain, which can develop permanent damage. These vitamins include B1, B6, and B12. You can get these essential vitamins through the consultation of the doctor. You can also check out Neuropathy Relief Guide to understand different ways of handling your condition with good vitamins and herbs. Benfotiamine, which is also vitamin B1, is said to reduce nerve pain by a high percentage. It is also used in getting rid of inflammation in the legs and hands.

On the other hand, vitamin B6 is recommended since it helps in covering nerve ends to avoid any further damages that may occur to the nervous system. However, it is advised that you do not take any extra dosage since it can interfere with the nerves leading permanent damage. Vitamin B6 has proven to improve the immune system, which is linked with healing any nerve damage present in the body.

2) Fish Oil

Nerve pain is a progressive condition that can lead to serious damage to the body organs. This is because it causes numbness and weakness to the body muscles. This way, you have a better approach method on how you can ensure your nerves are healthy. If you are undergoing chemotherapy or suffering from diabetes, it is easy to have complications like neuropathy. Therefore, you are advised to take fish oil, which is a natural medication. Through research, it was proven that fish oil is beneficial since it has an anti-inflammatory effect that has posed a positive impact on healing the nerves.

Moreover, it has shown to help in reducing pain and decreasing muscle soreness, which is a great challenge for most patients. Fish oil contains omega-3 fatty acids, which are the main acting agents in stimulating the growth of nerves instead of damaging. This is similar to vitamin B6, which is used in covering the ends of nerves to prevent further complications. Fish oil has been encouraged by most physicians since it is highly available and can help in healing other diseases that may be chronic. Moreover, it is a cheap product, yet it can have significant benefits in preventing any nerve pain.

3) Capsaicin

Herbal treatment has been there for decades, making it the best method of treating any disease due to its natural effect on the body. This is unlike other medications that come with side effects that may lead to permanent damage. Neuropathy is a manageable condition that requires a patients attention and effort to avoid pain. Capsaicin is a component found in pepper, which makes your mouth hot once you consume it. Despite its hotness, it has proved to be beneficial in the treatment of peripheral neuropathy. Here, you are required to apply it on the skin where it blocks any transmission of pain. It also comes into two forms, capsaicin cream, and capsaicin patches. These two have helped patients to avoid inflammation on the joints and muscles, making you relieve any pain present on the body. This is has been considered the most affordable herb for treating neuropathy since it is highly available and easy to use. The bottom line in this is that capsaicin makes the nerves numb and insensitive. Therefore, you cannot experience any pain. You are also recommended to use ginger or turmeric if you experience any allergic reactions with capsaicin. This way, it will be comfortable to ease pain rather than inducing any further problems.

Go here to read the rest:

3 Affordable Herbs & Vitamins that you should try for nerve pain relief - Explosion

Read More...

What You Need to Know About the FDA – Curetoday.com

Monday, December 30th, 2019

The Food and Drug Administrations accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

BY Kristie L. Kahl

The agency granted accelerated approval to the application for Padcev (enfortumab vedotin-ejfv) for this patient population, who had no standard of care prior.

Typically, for this patient population, there really wasn't anything that was active (in treating patients), and what weve seen is about 12% of patients have a complete tumor disappearance. Overall, about 40% of patients have whats called a partial response and 84% of patients have some form of tumor reduction, explained Dr. Daniel Petrylak, professor of medicine, medical oncology and urology, and co-leader of Cancer Signaling Networks, at Yale Cancer Center. So this is really a remarkable finding. To my knowledge, this is the most active single agent (in treating advanced bladder cancer). It is even more active than drugs they've been using in the earlier setting.

The agency based its decision on data from the multicenter, single-arm, phase 2 pivotal EV-201 trial designed to evaluate Padcev, which is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer, in 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy.

The first-in-class antibody-drug conjugate is approved under the FDAs Accelerated Approval Program, which allows approval of a medicine based on a surrogate endpoint if the medicine fills an unmet medical need for a serious condition. In this instance, the accelerated approval was based on tumor response rate, the studys primary endpoint.

We had a certain goal that we had to meet, which was 30%, and we exceeded that, Petrylak said. Patients demonstrated an objective response rate of 44%, including 15 complete responses (12%) and 40 partial responses (32%).

Moreover, duration of response, a secondary endpoint of the study, was 7.6 months.

The most common serious side effects were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%) and rash (3%). Peripheral neuropathy led to treatment discontinuation in 6% of patients. Common side effects of any grade included fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%).

Continued approval of Padcev will be contingent upon further evaluation to verify and describe the clinical benefit of the drug in a confirmatory trial.

There are a lot of next steps. This is an exciting drug, and it has a tremendous amount of activity, Petrylak said. Were looking to move this up earlier, in the course of disease. There's a trial being done in patients who've had frontline chemotherapy, and we're looking to (add Padcev) in the neoadjuvant setting prior to somebody having their bladder taken out. And so the thought is that perhaps we'll have more activity earlier.

Petrylak added that researchers are also looking to add the agent to other combinations, like checkpoint inhibitors.

Read CUREs original coverage of the approval.

Read more:

What You Need to Know About the FDA - Curetoday.com

Read More...

Looney gives up two aspects of diet to combat neuropathy – NBCSports.com

Sunday, December 15th, 2019

D'Angelo Russell is rapidly approaching a date some NBA observers have circled since the Warriors acquired him this summer.

Golden State can trade Russell as soon as Sunday, Dec. 15, and the 23-year-old has been the source of trade speculation during his time in the Bay Area. The Athletic's Jon Krawczynski reported Wednesday, citing sourcesthat the Minnesota Timberwolves "remain interested in Russell" and that the guard "seems to be realistic in understanding that he may not be long for the Warriors once Steph Curry and Klay Thompson return to full health."

Russell is averaging a career-high 22.4 points per game this season to go with 6.1 assists and 3.1 rebounds, serving as the top offensive option in the absence of his All-Star teammates. He knew he wouldn't play much with Thompson this season as he recovers from a torn ACL, but Curry's broken hand threw a wrench into the Warriors' -- and thus Russell's -- prospects this season. Warriors coach Steve Kerr praised how Russell has handled the rumors surrounding him.

"Money doesn't buy peace of mind," Kerr said Friday morning (H/T San Francisco Chronicle's Connor Letourneau)."It doesn't buy a sense of belonging, a sense of, 'Alright, this is my team.' If there's speculation that you're going to be traded all the time, I don't care how much money you make, I don't care who you are. That's tough. That's no fun to deal with, and this season has been nowhere close to what D'Angelo thought it would be when he first signed with us.

"There's no Steph. We're struggling to win games. He's had his own injuries, and we're throwing all kinds of different lineups out there based on the other injuries we've faced."

Russell has played in just 15 of the Warriors' 27 games this season, playing on a team that looksfar more like the Los Angeles Lakers of his first two seasons than the playoff-contending Brooklyn Nets a year ago -- let alone the reigning Western Conference champion Warriors.

[RELATED:How Warriors' Chriss earning chance to start at center]

Kerr, who entered this season with the highest winning percentage in NBA history (.785), is as aware of Golden State's dramatically different reality as anyone. He said it has only brought out the best in Russell.

"So given all that, he's played really well, and he's been a great teammate and he's doing everything he needs to do to solidify his position here," Kerr continued."But this is the NBA here, and we never know what's coming, what's happening. So, it's a difficult position to be in in general, but for him in particular it's strange set of circumstances and he's handling it really well."

Whether or not the Warriors trade Russell, it's clear Kerr holds him in high regard.

Excerpt from:

Looney gives up two aspects of diet to combat neuropathy - NBCSports.com

Read More...

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic…

Sunday, December 15th, 2019

First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial

Data to be presented today in an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS)

BUFFALO, N.Y., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced results from a pivotal Phase III clinical trial showed oral paclitaxel and encequidar had superior response and survival with much lower incidence and severity of neuropathy compared to IV paclitaxel in the treatment of metastatic breast cancer. For additional details on the study results, please refer to the abstract GS6-01, which can be found online here.

Dr. Rudolf Kwan, Chief Medical Officer of Athenex, commented, Oral paclitaxel and encequidar is the first oral taxane to demonstrate in a Phase III study statistically significant improvement in response rate and median overall survival compared to IV paclitaxel, in the treatment of metastatic breast cancer while associated with a much lower incidence and severity of neuropathy. We believe these data suggest the potential for oral paclitaxel and encequidar to provide an important advance in the management of patients with metastatic breast cancer.

These results will be presented in an oral presentation today at the 2019 San Antonio Breast Cancer Symposium (SABCS) at 3:15 p.m. CT in General Session 6 in Hall 3 of the Henry B. Gonzalez Convention Center in San Antonio, Texas, and were selected for the official SABCS press program at 7:30 a.m. CT.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next-generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Companys current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on nonabsorbed P-glycoprotein inhibition, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) arginine deprivation therapy. Athenexs employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit http://www.athenex.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as anticipate, believe, continue, could, estimate, evaluate, expect, foresee, guidance, intend, investigate, likely, may, plan, potential, predict, preliminary, prepare, potential, probable, project, promising, seek, should, will, would, and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third partiesfor success in certain areas of Athenexs business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to integrate CIDALs assets into our existing operations; competition; intellectual property risks; risks relating to doing business inChina; the uncertainty of when, if at all, we will be able to resume producing API in ourChongqingplant; and the other risk factors set forth from time to time in ourSECfilings, copies of which are available for free in the Investor Relations section of our website athttp://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-secor upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTSAthenex, Inc.:Jacqueline LiCorporate Development and Investor RelationsEmail: JacquelineLi@athenex.com

Investor Relations:Tim McCarthyManaging Director, LifeSci Advisors, LLCDirect: 212-915-2564

See the original post here:

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic...

Read More...

Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 – 2029 – Markets Gazette…

Sunday, December 15th, 2019

Assessment of the Chemotherapy Induced Peripheral Neuropathy Market

The latest report on the Chemotherapy Induced Peripheral Neuropathy Market published by Persistence Market Research (PMR) is a valuable tool for established and upcoming market players to solidify their presence in Chemotherapy Induced Peripheral Neuropathy Market landscape. Further, by leveraging the real-time and result-driven insights included in the report, readers can formulate effective business strategies to gain an advantage in the competitive nature of the market.

The presented study suggests that the Chemotherapy Induced Peripheral Neuropathy Market is expected to attain a value of ~US$ XX by the end of assessment period and grow at a CAGR of ~XX% during the forecast period, 2019 2029. The underlying trends, growth opportunities, market drivers, and challenges faced by companies in the Chemotherapy Induced Peripheral Neuropathy Market are analyzed in detail.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/30209

Vital Information Included in the Report:

The competitive landscape chapter of the report provides valuable insights related to the business prospects of some of the leading companies in the Chemotherapy Induced Peripheral Neuropathy Market. The product portfolio, pricing structure, revenue growth, and footprint analysis of each market players are included in the report.

Important Queries Related to the Chemotherapy Induced Peripheral Neuropathy Market Addressed in the Report

The dynamics of the Chemotherapy Induced Peripheral Neuropathy Market across major geographical regions are included in the report and represented in the study. In addition, to provide a frictionless reading experience the data is depicted using informative graphs and other graphical illustrations.

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/30209

key players and product offerings

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/30209

What Makes PMR Different?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- Website:

Read more from the original source:

Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 - 2029 - Markets Gazette...

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Industry…

Sunday, December 15th, 2019

A profound analysis of the industry based on the "Chemotherapy Induced Peripheral Neuropathy Treatment Market" all over the world is named as Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report. The research report assesses the current as well as the upcoming performance of the Chemotherapy Induced Peripheral Neuropathy Treatment market, in addition to with newest trends in the market. The major player of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma)are also included in the market report. The report forecasts the future of the Chemotherapy Induced Peripheral Neuropathy Treatment market on the basis of this evaluation.

The research analysis for Chemotherapy Induced Peripheral Neuropathy Treatment market comprises each and every feature of the market all over the world, which starts from the Chemotherapy Induced Peripheral Neuropathy Treatment market description and ends on the Chemotherapy Induced Peripheral Neuropathy Treatment market segmentation (Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others). In addition to this, each section of the Chemotherapy Induced Peripheral Neuropathy Treatment market is categorized and evaluated on the basis of goods, the end-user clients of the Chemotherapy Induced Peripheral Neuropathy Treatment market, and the employment of the products. The geographical categorization of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Platinum Agents, Taxanes, Vinca Alkaloids, Others) has also been evaluated thoroughly in the report.

Ask for sample link here: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html#request-sample

The Chemotherapy Induced Peripheral Neuropathy Treatment perusers will discover this report exceptionally advantageous in the comprehension of the Chemotherapy Induced Peripheral Neuropathy Treatment showcase in the nitty-gritty. The angles and data are spoken to in the Chemotherapy Induced Peripheral Neuropathy Treatment report utilizing figures, structured presentations, pie graphs, and other visual portrayals. This escalates the Chemotherapy Induced Peripheral Neuropathy Treatment pictorial portrayal and furthermore helps in getting the Chemotherapy Induced Peripheral Neuropathy Treatment business actualities much better. The Chemotherapy Induced Peripheral Neuropathy Treatment advertise is probably going to develop at a noteworthy CAGR. The principle goal of the Chemotherapy Induced Peripheral Neuropathy Treatment report is to direct the client to comprehend the Chemotherapy Induced Peripheral Neuropathy Treatment advertise as far as its definition, order, Chemotherapy Induced Peripheral Neuropathy Treatment showcase potential, most recent patterns, and the difficulties that the Chemotherapy Induced Peripheral Neuropathy Treatment advertises is confronting.

Questions replied in this Chemotherapy Induced Peripheral Neuropathy Treatment report: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html

1. What will the Chemotherapy Induced Peripheral Neuropathy Treatment advertise projection and what will the advancement rate by 2024?

2. What are the major Chemotherapy Induced Peripheral Neuropathy Treatment advertise designs?

3. What is the development of driving components of the Chemotherapy Induced Peripheral Neuropathy Treatment industry?

4. What are the snags being developed to the Chemotherapy Induced Peripheral Neuropathy Treatment showcase?

5. Who are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers in a market?

6. What are the market space and limitations by the Chemotherapy Induced Peripheral Neuropathy Treatment key sellers?

7. What are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers quality through SWOT and PESTEL consider?

Another area of the Chemotherapy Induced Peripheral Neuropathy Treatment advertise report uncovers the procedure of creation. Be that as it may, this procedure gauges nitty-gritty Chemotherapy Induced Peripheral Neuropathy Treatment think about with respect to assembling cost which incorporates crude stock, and diverse providers for modern offices.

Enquire about our report with our industry authority:

Overall Chemotherapy Induced Peripheral Neuropathy Treatment Market Report Importance:

Our report significantly fixates around genuine research on each part and its general result on the Chemotherapy Induced Peripheral Neuropathy Treatment showcase advance.

The objective gathering of watchers of the Chemotherapy Induced Peripheral Neuropathy Treatment report acclimatizes new wannabes planning to wind up an expansive comprehension of the business, masters, monetary establishments, real accomplices, profitability, Chemotherapy Induced Peripheral Neuropathy Treatment wholesalers, and industry organization.

To get the examination techniques those are being gathered by Chemotherapy Induced Peripheral Neuropathy Treatment driving individual associations.

To have the misgiving without obstacles Chemotherapy Induced Peripheral Neuropathy Treatment stance and a probability for the market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

About Us Market and Research are a trusted brand in the research industry with the capability of commissioning complex projects within a short span of time with a high level of accuracy. At Market and Research, we believe in building long term relations with our clients. Our services cover a broad spectrum of industries including Energy, Chemicals and Materials, Automotive and Aerospace.

Contact Us: Market and Research United States

Read the original here:

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry...

Read More...

Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -…

Sunday, December 15th, 2019

Latest market research report On Neuropathy Pain Treatment Market from Ample Market Research covers market overview- defines characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for the Neuropathy Pain Treatment industry. The market size section gives the market revenues, covering both the historic data of the market and forecasting the future. Drivers and restraints are studied with respect to external factors influencing the growth of the market. Industry segmentations breaks down the key sub-sectors which make up the market. Additionally, the report also highlights market entry strategies for various companies across the globe. Some of the key players operating in this market include Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals.

Get a complete & Professional sample PDF of the Neuropathy Pain Treatment market report at https://www.amplemarketreports.com/sample-request/global-neuropathy-pain-treatment-market-1248476.html

The report provides insightful and comprehensive information in consideration of the different industry pioneers, including their revenue details, technological advancements, innovations, key developments, SWOT analysis, mergers & applications, future strategies, and market footprint. On the basis of segmentation, the market has been classified into product type, the technologies used, end-user, industry vertical, and geography.

Key companies profiled in this report are Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals and more. These companies are profiled in terms of company basic details, business overview, product knowledge, historical revenue, and recent developments.

The report offers thorough information about the overview and the scope of the Neuropathy Pain Treatment market along with its drivers, restraints, and trends. It also classifies the market into different segments such as by type, by applications and by-product

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into Calcium channel alpha 2-delta ligands, Serotonin-norepinephrine reuptake inhibitors, Others.

In terms of region, this research report covers almost all the major regions across the globe such as Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Oceania], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]

Split by application, this report focuses on consumption, market share and growth rate of Neuropathy Pain Treatment in each application.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.amplemarketreports.com/report/global-neuropathy-pain-treatment-market-1248476.html

The study objectives are:

To analyze and research the Neuropathy Pain Treatment market status and future forecast? involving, production, revenue, consumption, historical and forecast.

To present the key manufacturers, production, revenue, market share, and development plans in the next few years.

To segment the breakdown data by regions, type, manufacturers, and applications of Neuropathy Pain Treatment market.

To analyze the global keyword market opportunity, drivers, challenge, and restraints.

To identify significant trends, influence factors of Neuropathy Pain Treatment market.

To evaluate each submarket with respect to individual growth trends and their contribution to the market.

To examine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

This report can be customized to meet your requirements. Please connect with our sales team who will ensure that you get a report that suits your needs.

https://www.amplemarketreports.com/enquiry-before-buy/global-neuropathy-pain-treatment-market-1248476.html

Lastly, the Neuropathy Pain Treatment Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Neuropathy Pain Treatment market.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

Read the original here:

Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -...

Read More...

Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – World Industry Reports

Sunday, December 15th, 2019

The research report Neuropathy Pain Treatment Market Global Industry Analysis 2019 2025 offers precise analytical information about the Neuropathy Pain Treatment market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Neuropathy Pain Treatment Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Neuropathy Pain Treatment industry.

This Neuropathy Pain Treatment market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Neuropathy Pain Treatment market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#RequestSample 

Competitive Landscape

Global Neuropathy Pain Treatment market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Market Segmentation

Neuropathy Pain Treatment Market report segmentation on Major Product Type:Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Others

Market by Application: Here, various application segments of the global Neuropathy Pain Treatment market are taken into account for the research study.

Retail Pharmacies, Hospitals, Others

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#InquiryForBuying

Regional Analysis

The Neuropathy Pain Treatment market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Neuropathy Pain Treatment Market Report:-

What will the market growth rate, overview, and analysis by type of global Neuropathy Pain Treatment Market in 2026?

What are the key factors driving, analysis by applications and countries Global Neuropathy Pain Treatment Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Neuropathy Pain Treatment Market?

Who are the opportunities, risk and driving forces of the global Neuropathy Pain Treatment Market?

Who are the opportunities and threats faced by the vendors in the Global Neuropathy Pain Treatment Market?

What are the Global Neuropathy Pain Treatment market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

More:

Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - World Industry Reports

Read More...

Health watch: 5 things to know about chemotherapy – StarNewsOnline.com

Sunday, December 15th, 2019

New medicines and treatments can often help patients better tolerate the sometimes harsh side effects of chemo

Chemotherapy, or chemical treatment, is often recommended as a treatment for a variety of cancers as it uses powerful chemicals to kill fast-growing cells, such as cancer cells, in ones body. Particularly for cancer that has spread to different parts of the body beyond the original tumor, chemotherapy can be effective as it can work throughout the whole body. According to the American Cancer Society, the three main goals for using chemotherapy in cancer treatment are to cure cancer, to control the disease if a cure isnt possible and palliation, to ease symptoms.

Dr. Lindsey Prochaska, DO, a medical oncologist with NHRMC Physician Group - Cape Fear Cancer Specialists, and Katie Evans, an oncology clinical pharmacist at NHRMC, have shared some information about this common cancer-fighting treatment, often called chemo. Prochaska treats patients at Cape Fear Cancer Specialists office in Leland and at New Hanover Regional Medical Centers Zimmer Cancer Center, and Evans collaborates with the oncology teams and patients at the Zimmer Cancer Center.

1) Chemotherapy can be used alone or along with other treatments

Sometimes chemotherapy is the only treatment a patient may need to treat a cancer, other times it may be used along with other forms of treatment.

"Chemotherapy can be used after surgery, before surgery, or even in the metastatic non-curable setting for control of cancer, said Prochaska. In the setting in which surgery removes a cancer, chemotherapy is often used before or after the surgery to rid the bloodstream of cells to reduce recurrence.

Some cancers respond to chemotherapy better than others, and Prochaska said chemotherapy may not be recommended in some circumstances.

More aggressive cancers sometimes respond better to chemotherapy than slow growing ones, she said. Very few cancers have no role for chemotherapy, but if a cancer is caught at a very early stage chemo may not be recommended.

As for if chemotherapy can sometimes provide a complete cure, Prochaska said, Absolutely. When given before or after surgery cure is commonly the goal, she said.

2) Chemotherapy drugs can be taken orally or received through ones veins

Chemotherapy is most often administered intravenously (IV), although, there are some oral chemotherapy treatment options, Evans said. Chemotherapy is administered by chemotherapy certified nurses in the infusion center, whereas, the oral options patients can self-administer following safety precautions for hazardous medications.

3) Chemotherapy can also treat other conditions

Chemotherapy is mostly only used for cancer, but there are some targeted therapies and conventional chemotherapies that treat autoimmune diseases, like lupus and rheumatoid arthritis, Prochaska said.

4) Chemotherapy can reduce chances of a cancer returning

The side effects of chemo can be harsh, but many times when recommended, its to increase the chances of cure, Prochaska said. Chemo can reduce the chances of recurrence 25-50% -- sometimes higher.

5) Side effects are common with chemotherapy

It is true that most systemic chemotherapy can affect both healthy and cancer cells in causing cell death, Evans said. Chemotherapy targets fast growing cells inside of the body which can be both cancer cells and healthy cells. Herein lies the potential for side effects. With newer, more targeted therapy and immunotherapy coming into use, we have seen the potential for side effects to lessen as compared to traditional, systemic chemotherapy.

Evans said these targeted therapies still have side effects that are manageable by an oncologist.

As clinical oncology pharmacists we counsel patients on the side effects they may experience, timeline, and management of the particular side effects with the chemotherapy regimen, she said.

Evans said some common side effects of chemotherapy include lowering blood counts, nausea, vomiting, gastrointestinal disturbances, peripheral neuropathy, hair loss, appetite and taste changes.

Side effects from chemotherapy are common, but can be managed with supportive care medications, Evans said. Once chemotherapy is completed, many side effects will resolve, though we know that some side effects like hair loss and neuropathy will take months to resolve.

Evans said side effects with chemotherapy treatment also differ in the time of onset. The effects on blood cell counts are relatively soon after chemotherapy has begun, hair loss is usually between 2-3 weeks after chemotherapy, and neuropathy may take several weeks before noticing.

Contrary to what some may think, Evans said not all types of chemotherapy cause hair loss.

Prochaska said medications have made a difference regarding some side effects.

Chemotherapy premedications and postmeds have come a long way, Prochaska said. Many people tolerate chemotherapy much better than expected now that we have medications that can help control nausea and vomiting.

Contact the newsroom at 910-343-2384 or Breakingnews@StarNewsOnline.com.

The rest is here:

Health watch: 5 things to know about chemotherapy - StarNewsOnline.com

Read More...

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma – OncoZine

Sunday, December 15th, 2019

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) and nivolumab (Opdivo; BristolMyers Squibb) in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical Hodgkin lymphoma were presented at the 61st annual meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Florida.

According to the American Cancer Society, approximately 8,110 cases of Hodgkin lymphoma will be diagnosed in the United States during 2019 and 1,000 will die from the disease. Approximately half of all newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with Hodgkin lymphoma each year and approximately 25,000 people die each year from this cancer.

Antibody-drug conjugateBrentuximab vedotin is an antibody-drug conjugate or ADC directed to CD30, a defining marker of classical Hodgkin lymphoma. The drug includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Antibody-drug Conjugates are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

Continued evaluationWe continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need, said Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.

The data presentations at the annual meeting reinforces our strong commitment to the brentuximab vedotin clinical development program, potentially moving into new patient populations and novel combination treatment strategies, Dansey added.

Frontline therapyData were presented from an updated analysis from the phase II clinical trial evaluating brentuximab vedotin in combination with nivolumab as frontline therapy for Hodgkin lymphoma patients aged 60 years and older. Data were reported from 21 patients, and the median age was 72 years. The majority of patients (76%) had stage III/IV disease at the time of diagnosis.

These results were highlighted in an oral presentation by Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Oregon. [1]

The trial included 19 response-evaluable patients, 18 patients (95%) had an objective response, including 13 patients (68%) with a complete response and five patients (26%) with a partial response.

All response-evaluable patients experienced tumor reduction (complete response + partial response + stable disease) following treatment with brentuximab vedotin in combination with nivolumab. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing (95% CI: 7.06, -).

The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.

One treatment-related serious adverse event was pyrexia. Fifty-seven percent of patients (12/21) had at least one treatment-related adverse event greater than or equal to Grade 3, most commonly increase in lipase (24%, 5/21), peripheral motor neuropathy and peripheral sensory neuropathy (each 14%, 3/21), and fatigue and hyponatremia (each 10%, 2/21).

These data suggest that brentuximab vedotin + nivolumab is an active treatment with an encouraging CR rate (72%) and appears well tolerated. The results also suggest that with further follow-up and validation, treatment with brentuximab vedotin + Nivo may improve patient outcomes.

Relapsed or Refractory Hodgkin LymphomaA second presentation reported data from 93 patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy who received the combination regimen of brentuximab vedotin plus nivolumab.

After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 34 years.

These results were highlighted in an oral presentation by Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY. [2]

The study results of this trial showed that of the 91 treated patients, 85% (77/91) had an objective response, including 67% (61/91) with a complete response, 16 patients with a partial response and six patients had stable disease.

From the ninety-one treated patients, sixty-seven patients received an ASCT per trial protocol with no additional salvage therapy. For all treated patients, the two-year progression-free survival (PFS) was 79% (95% CI: 68%, 87%). For the 67 patients who received an ASCT per trial protocol, the two-year PFS was 92% (95% CI: 80%, 97%). Median follow-up for all treated patients was 24.2 months (range 1.8-41.7) and the median PFS was not reached. Estimated overall survival at two years was 94% (95% CI: 85%, 97%) and median overall survival was not yet reached.

Peripheral immune signatures were consistent with an activated T-cell response. Prior to ASCT, the most common adverse events of any grade occurring in more than 20% of patients were nausea, infusion related reaction, fatigue, diarrhea, pruritus, headache, vomiting and pyrexia. Other adverse events included peripheral neuropathy in 16 patients (18%) and neutropenia in six patients (7%). Two patients (2%) discontinued treatment due to adverse events, Grade 3 peripheral neuropathy and increased gamma-glutamyltransferase. Serious adverse events occurred in 14 patients (15%), including pneumonia, pneumonitis and pyrexia (two patients each); and Grade 3 Guillain-Barre syndrome (one patient).

Reference[1] Yasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, Newhook T, Mei M, et al. Phase II Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 60 Years. 61st annual meeting of the American Society of Hematology (ASH). Program: Oral and Poster Abstracts. Type: Oral. Abstract 237. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma Hematology Disease Topics & Pathways: Diseases, Biological, antibodies, Therapies, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies.[Abstract][2] Moskowitz AJ, Advani R, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, et al. Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase I/II Study. 61st annual meeting of the American Society of Hematology (ASH).Program: Oral and Poster AbstractsType: Oral Abstract 238. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma. Hematology Disease Topics & Pathways:Diseases, Biological, Therapies, Hodgkin Lymphoma, checkpoint inhibitors, immunotherapy, Lymphoid Malignancies. [Abstract]

Read more here:

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine

Read More...

Medical News Today: Lung cancer complications: Signs, treatment, and outlook – Stock Daily Dish

Sunday, December 15th, 2019

Cancer is a disease caused by unhealthy cells inside the body growing out of control. Lung cancer is the uncontrolled growth of abnormal cells that start off in one or both lungs.

In the United States, is the form of . It is also the most common cause of cancer death in the U.S.

Contents of this article:

Lung cancer can cause a number of complications in the lungs and in other parts of the body. Here are some of the most common complications:

Some of the more common lung cancer symptoms are caused by complications in the lungs.

According to , these complications can lead to the following symptoms:

Pneumonia is a possible symptom of complications in the lungs caused by cancer.

is numbness and tingling feelings in the hands and feet due to damaged nerve tissue. It can be a .

Neuropathy is caused by tumors that grow near the nerves in the arm or shoulder. A compresses the nerves leading to pain and weakness.

This is the in the membrane that covers the lungs. The fluid can then press against the lungs causing breathlessness.

Lung cancers can sometimes affect the heart when they develop near it or close to major blood vessels. This can cause fluid to press against the heart, which may lead to a number of issues.

These issues include:

Depending on its location, a tumor may block a persons airways or food pipe.

A tumor may grow into an airway in the lung and block it. This may lead to other issues, such as pneumonia or shortness of breath.

Lung cancers that grow near a persons food pipe can cause complications, making it difficult for the person to swallow.

Cancers near a foodpipe may lead to a person feeling pain when food passes through to their stomach.

Another serious complication of lung cancer is that it may spread to other parts of the body. Some lung cancer cells can travel through the lymphatic system or through the bloodstream.

If this happens, the cells can become lodged somewhere else in the body. Cancerous cells can then grow in these new locations, causing further cancers.

According to , lung cancer is most likely to spread to:

There are a number of ways to treat all of these different complications. The choice of treatment will vary depending on a number of factors, which include the type of complication, the age, and the general health of the patient.

Here are different treatments for the variety of complications listed above:

Numbness and tingling in the hands or feet may be treated with medication.

Neuropathy as a complication of lung cancer can lead to discomfort. There are many ways to treat the symptoms of neuropathy, including:

Pleural effusion can be treated by slowly draining away the fluid. In order to do this, a tube is inserted into the chest through a small cut.

A person may spend a few days in hospital after this treatment. If the fluid builds up again, they may need to have it drained a further time.

A person with pleural effusion may also have one of the following procedures:

Heart complications can occur if fluid presses against blood vessels because of a tumor. This can be treated in the following ways:

There are a number of procedures to treat lung cancer if it blocks a persons airways. These include the following:

Complications caused by lung cancer can occur over time. They tend to appear as the disease develops.

If a persons lung cancer is detected early, then they have a much higher chance of surviving the disease. Its important for a person to understand the symptoms so that they can get an early diagnosis.

Unfortunately, most cases of lung cancer are diagnosed in the later stages. This is because many of the symptoms or complications of the disease tend not to occur until the cancer is advanced.

Therefore, the individual outlook depends on a number of factors including the type of cancer, how far it has developed, and the persons age and general health.

Written by Adam Rowden

Follow this link:

Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish

Read More...

Pain under left armpit: Causes and what to do – Medical News Today

Saturday, November 30th, 2019

Pain under the left armpit can be concerning, and many people associate any pain on the left side of their body with a heart attack. However, most of the time, pain under the left armpit has a less serious cause.

The armpit is a complex meeting point for muscles and connective tissues, lymph nodes, and blood vessels. As such, many issues in this area can lead to pain.

Causes range from pulled muscles and mild allergic reactions to more severe issues, such as an underlying infection.

While many of the causes of left armpit pain are not harmful in the long term, anyone experiencing breathing difficulties and pain in their chest, jaw, or neck should see a doctor immediately.

Causes of left armpit pain include:

Many muscles around the shoulder and armpit can cause pain if a person injures them.

People can pull a muscle when reaching for an object, twisting incorrectly, or overstretching.

People who exercise regularly, especially those who do weight training, may be more likely to experience muscle pulls and strains.

In these cases, the pain should go away over time, as long as the individual rests the injured muscle and does gentle stretches.

If the pain does not go away after about a week, it is best to see a doctor.

Armpits are a frequent location for allergic reactions, which could cause pain under the left armpit or both armpits.

Most allergic reactions in this area will occur due to chemicals people apply to their bodies or clothes that touch the armpits.

Possible allergens include:

These products may contain chemicals or perfumes that irritate the skin. A rash may also form.

Anyone who suspects that their skin is sensitive to a particular allergen should note the products they used that day and report them to a dermatologist.

Allergy testing may help find the irritating product. Avoiding products with any harsh chemicals or other ingredients can also improve symptoms in these cases.

Simple cosmetic procedures, such as shaving or waxing, can also be to blame for pain under the armpit. These hair removal techniques may lead to other issues, such as ingrown hairs, cysts, or general irritation and chafing in the armpit.

A skin infection under the armpit may cause itching and pain. Bacteria thrive in warm, damp environments such as the armpits.

An overgrowth of bacteria in this area may lead to an infection, which could cause redness, swelling, and pain, among other symptoms.

Other forms of infection, such as fungal infections due to ringworm or yeast, may also cause similar pain and irritation in the area.

Mild skin infections should clear up without treatment if a person keeps the area clean and dry. However, a doctor may recommend antibiotic creams or medications to treat more severe cases.

Hidradenitis is a chronic condition that causes similar symptoms to severe acne. Hidradenitis occurs due to clogged hair follicles and glands. It is common in areas such as the armpits, where the skin rubs together.

Hidradenitis can lead to multiple cysts or boils developing in the area. In addition to these breakouts, the person will likely experience pain and tenderness.

Doctors can treat hidradenitis with anti-inflammatory medications. Some cases may require surgery.

The varicella zoster virus causes chickenpox and shingles. Breakouts of both illnesses are possible under the armpits, although chickenpox usually begins on the face, back, and chest.

A shingles rash usually develops as a single strip on one side of the face or body, left or right. A person with shingles may also experience:

A person may feel pain and tingling in the area before the visible rash develops.

A doctor may prescribe antiviral medications to speed up the healing process, as well as pain medications to help ease symptoms.

Lymph nodes are small, bean shaped bundles of tissue that play a vital role in the immune system. Lymph nodes help filter toxins from the lymph and deliver white blood cells to help fight disease.

The armpit houses a large number of lymph nodes. Lymph nodes swell as part of an overall reaction by the immune system, such as to an infection or illness.

Swollen lymph nodes in the armpit may cause:

If the swelling does not go down after an infection, such as the common cold, goes away, or the person is not feeling any other symptoms, they should speak to a doctor.

Psoriasis is an autoimmune condition that leads to an overgrowth of skin cells. The buildup of skin cells forms patches called plaques. These plaques can cause symptoms such as itching and pain.

Psoriasis plaques can form anywhere, including the armpit. Some forms of psoriasis are more common in this area, including inverse psoriasis.

Psoriasis treatment typically includes both topical and oral medications to control symptoms.

Nerve damage may also cause pain under the armpit. Nerve damage can be the result of a physical injury, such as one from overuse during sports or from an accident or fall.

Nerve damage can feel like:

Certain conditions, such as diabetes, may also lead to nerve damage or neuropathy. The National Institute of Diabetes and Digestive and Kidney Diseases note that up to half of people with diabetes have peripheral neuropathy, which is nerve damage.

While peripheral neuropathy typically affects the feet and legs, it may also affect the arms in some individuals. Diabetes treatment may help slow nerve damage progression.

Angina occurs due to a lack of oxygen-rich blood flow to the heart. This can be because one of the arteries leading to the heart is narrow or blocked.

Angina causes chest pain and discomfort, which is sometimes severe. It may also cause pressure and pain in other areas, including the:

Some people may also experience a feeling similar to indigestion.

Angina is a symptom of an underlying heart condition, for example, coronary heart disease, which can lead to a heart attack.

There are also many other types of angina. Anyone who suspects they have angina should talk to their doctor.

In rare cases, pain under the left armpit that does not go away may be a sign of a cancerous growth, including breast cancer.

Cancer can cause the lymph nodes under the armpit to swell painfully. An individual may notice a lump under their arm or in their armpit that causes persistent pain or discomfort.

Underarm pain may also be the result of a specific cancer treatment, such as lymph node removal or mastectomy.

Anyone noticing texture changes or lumps in their chest or breast tissue should seek medical attention.

Treatment options for cancer will depend on its stage, which refers to how much it has spread. In general, earlier stages are easier to treat.

Anyone noticing the following symptoms along with left armpit pain should seek immediate medical attention:

A doctor can also diagnose and treat pain from other issues, such as infections or swollen lymph nodes.

Pain under the left armpit from sources such as a pulled muscle should go away within about a week in most cases. Anyone who experiences symptoms beyond this time frame should see a doctor for a full diagnosis.

There are many possible causes of pain under the left armpit. The person may have pulled a muscle or may have swollen lymph nodes from an infection.

Other causes can be more serious, such as angina. Anyone concerned about their symptoms should see a doctor for a full diagnosis and treatment.

Originally posted here:

Pain under left armpit: Causes and what to do - Medical News Today

Read More...

Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma – Oncology Nurse…

Friday, November 29th, 2019

Results of a recent study suggest a possible role for tumor necrosis factor- (TNF-) in the development of peripheral neuropathy (PN) in patients with multiple myeloma (MM) treated with bortezomib. The studys results were published in the Annals of Hematology.

Inthis study, patients with MM (N=35) were given a maximum of 8 cycles ofbortezomib in addition to dexamethasone. Patients underwent tests of nervefunction, and their serum levels of TNF- were also measured. This study alsoincluded an analysis of the effects of an anti-TNF- monoclonal antibodytherapy in Wistar rats (N=36) that received bortezomib.

Evaluablepatients were stratified based on the cumulative dosages of bortezomib theyreceived. A total of 16 patients (48.5%) had cumulative dosages of less than 39mg/m2, and 17 (51.5%) each received 39 mg/m2 or more of bortezomib.

Amongpatients who received lower cumulative dosages of bortezomib, 43.8% (n=7)experienced PN, compared with an incidence of PN of 82.4% (n=14) among patientswho received 39 mg/m2 or more of bortezomib (P <.05).Grade 3 PN was reported for 2 patients in the higher-dose group.

Baselineserum TNF- levels did not significantly differ between patients whoexperienced PN and those who did not. With bortezomib treatment, TNF- levelsrose overall, but increases were most significant among patients who developedPN of grades 2 to 3. The investigators also reported that most patients withTNF- levels higher than 65 pg/mL had neuropathy symptoms.

Inthe rat model, poorer nerve conduction velocity and evidence of mechanicalallodynia appeared to be associated with bortezomib therapy. Among rats treatedwith bortezomib, however, treatment with the anti-TNF- monoclonal antibody wasassociated with less neurological dysfunction.

Developmentof new neuroprotective agents against TNF- may be a promising therapeuticstrategy to prevent the development of neuropathy, wrote the studyinvestigators in their report.

Reference

Zhao W, Wang W, Li X, et al. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-. Ann Hematol. doi: 10.1007/s00277-019-03816-6

Read more from the original source:

Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse...

Read More...

Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate – Montana Ledger

Friday, November 29th, 2019

Thediabetic neuropathy markethas witnessed growth from relentless efforts of various healthcare proponents in expanding the array of various therapies and first line drugs in treating the underlying pain. Players have been able to meet the patient needs because of expanding understanding of physiopathology that promote neuropathic pain in diabetes. Most first line drug therapies notably focus on mitigating toxic effects of hyperglycemia. Several players in the diabetic neuropathy market have been benefitting from the introduction of guidelines that help develop therapies that can optimize pain.

The competitive landscape of the diabetic neuropathy market is characterized by fair degree of fragmentation. A handful of players hold sizable shares in the market. Top names in the diabetic neuropathy market are Janssen Pharmaceuticals, Eli Lilly and Company, Cephalon, NeuroMertrix, and Johnson and Johnson. One of the key strategies they increasingly adopt to consolidate their shares is mergers and acquisitions.

During 2017 2025, the global diabetic neuropathy market is expected to clock a CAGR of 5.4%. By the end of this period, the worth of the global market is anticipated to be US$5.718 bn.

Request a PDF Sample of Diabetic Neuropathy MarketReport

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

Prevalence and Complexity Of Diabetic Peripheral Neuropathy Represents Unmet Need

Of the various disorder types, diabetic peripheral neuropathy has attracted the attention of pharmaceutical and biotech companies. By 2025-end, the segment is expected to account for a major share in the global diabetic neuropathy market. The complexity of the type has attracted vast attention of the healthcare industries around the world. The marked prevalence of diabetic peripheral neuropathy adds to its disabling nature. The higher mortality and morbidity of distal symmetrical polyneuropathy is also propelling investments in this area in the global diabetic neuropathy market.

In developed nations, the prevalence of diabetes is increasing at rapid pace. According to recently disclosed statistics by International Diabetes Federation, by 2045 629 million people will be living with diabetes, and currently account for more than 12% of the total spending by adult populations. One of the most complication is diabetic neuropathy. Hence, the condition has attracted groundswell of interest in these nations, such as in the U.S. and the U.K. Further, in recent years, a fast emerging category that is attracting attention of companies in the diabetic neuropathy market is treatment-induced neuropathy in diabetes. Constant advances in understanding of the underlying pathogenesis of diabetic peripheral neuropathy over the last decade have expanded the prospects of the diabetic neuropathy market.

Request for a Discount on Diabetic Neuropathy Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2199

Asia Pacific Fast Emerging as Key Diabetic Neuropathy Market

In the light of developed markets, North America and Europe have emerged as prominent regional markets. A shared factor underpinning the evolution of both these markets are expanding interest in pathophysiological mechanisms. On the other hand, Asia Pacific is emerging as a vastly lucrative region in the global diabetic neuropathy market. This is attributed to the substantial clinical developments in understanding diabetic complications.

Expanding Pharmacological Classes of Drugs Provides New Revenue Base

Lifesciences companies in the global diabetic neuropathy market find it worthwhile and necessary to develop therapies that can target multiple metabolic pathways. Key of these are hyperglycemia, toxic adiposity, mitochondrial dysfunction, and polyol pathway. Promising candidates to emerge in recent years are accumulation of advanced glycation end products (AGEs). Growing research on improving the clinical efficacy of antidepressants and anticonvulsants will likely expand the outlook of the global diabetic neuropathy market.

Of note, developed as developed markets are seeing expanding research in pharmacological classes of drugs. The development of these drugs is fueled by the adoption of multimodal and multidisciplinary approaches. Further, growing focus on developing second or third line treatment is also unlocking new potential in the diabetic neuropathy market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comBlog:https://theglobalhealthnews.com/

Read this article:

Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger

Read More...

Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 – chronicles24

Friday, November 29th, 2019

Damage to the nerves that control the regulation of involuntary function due to high levels of blood glucose may cause a condition called autonomic neuropathy. An example of body functions such as heart rate, digestion, blood pressure, sexual activity, and perspiration. Cardiac autonomic neuropathy occurs when the heart is affected by nerve damage. Diabetes mellitus patient commonly suffers from cardiac autonomic neuropathy. More than 26 million people in the Unites States get affected by diabetes mellitus. With the increase in age and duration of diabetes mellitus, a prevalence rate of cardiac autonomic neuropathy increase. Cardiac Autonomic Neuropathy is the reason for several cardiac dysfunctions and many medical symptoms which include exercise intolerance, silent ischemia, postural hypotension, resting tachycardia, perioperative instability, and cardiomyopathy.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/14518

Cardiac Autonomic Neuropathy treatment market involves aggressively treating cardiovascular risk factors like hypertension. Cardiac autonomicdeficiency of essential fatty acids, increased oxidative stress, autoimmune damage, and formation of advanced glycosylation end products. Other therapies include in Cardiac autonomic neuropathy treatment include Aldose reductase inhibitor and angiotensin receptor blocker.

Cardiac Autonomic Neuropathy Treatment Market: Drivers and Restraints

In diabetic patients, Cardiac Autonomic Neuropathy characterizes one of the main causes of morbidity and mortality as well as is responsible for cardiac arrhythmias and sudden death which is increasing the demand for cardiac autonomic neuropathy treatment market. Increase in aging population as the well societal influence and changing lifestyles are also the cause of increasing Cardiac autonomic neuropathy treatment market in the world. According to WHO report, more than 23 million people in the United States and an estimated 250 million worldwide are affected by diabetes mellitus. In diabetic patient Cardiac autonomic neuropathy is very common and leads to abnormalities in heart flow rate as well as vascular and peripheral dynamics and reduced quality of life are the drivers for Cardiac autonomic neuropathy treatment market. Some of the Cardiac autonomic neuropathy therapies has shown promising initial result but yet to be validated as well Cardiac autonomic neuropathy treatment management depends on aggressive strategies due to the absence of direct treatment could be the possible restraint for the Cardiac autonomic neuropathy treatment market. Poor reimbursement policies by government and private players also challenge the Cardiac autonomic neuropathy treatment market.

Cardiac Autonomic Neuropathy Treatment Market: Segmentation

Cardiac autonomic neuropathy treatment market is segmented into treatment type which includes pharmacological agents as well as inhibitors and by distribution channel.

Cardiac Autonomic Neuropathy Treatment Market: Overview

Due to increasing aging population and diabetes mellitus, the global market for Cardiac autonomic neuropathy treatment market is expected to gain pull during the forecast period. It is expected centrally acting Cardiac autonomic neuropathy treatment market segment to hold the dominant share in the global Cardiac autonomic neuropathy treatment market due to increasing number of diabetic patients. Also, the increase in number launches of the new drugs cardiac autonomic neuropathy treatment market is increasing globally. Increasing competition among ading drug firms in the market to develop newer drugs tends to drive the cardiac autonomic neuropathy treatment market towards the growth rate.

Cardiac Autonomic Neuropathy Treatment Market: Region-wise Outlook

Based on geographic region, the Cardiac autonomic neuropathy treatment market is segmented into seven significant regions:

North America, Latin America, Europe, Asia-pacific, and Middle East & Africa.

North America is the largest in Cardiac autonomic neuropathy treatment market, owing to high number of diabetes mellitus patient and awareness among patients regarding the harmful effects orpulation as well as growing healthcare expenditure is the reason for significant revenue generation from this region in Cardiac autonomic neuropathy treatment market. Europe is the second largest in Cardiac autonomic neuropathy market due to advancement in technologies and change in lifestyles.

Asia-Pacific is expected to grow at faster rate in the upcoming period due to the increase in the prevalence of diabetes mellitus thus boosting the Cardiac autonomic neuropathy treatment market growth.

Make An Inquiry To Customize This Report @https://www.persistencemarketresearch.com/request-customization/14518

Cardiac Autonomic Neuropathy Treatment Market: Key Market Participants

Some of the key players in Cardiac autonomic neuropathy treatment market are

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Read more:

Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24

Read More...

Page 19«..10..18192021..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick